Holen Sie sich die Stockscreener-App
7.30
2.67%
0.19
Handel nachbörslich:
7.70
0.40
+5.48%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Capricor: Q1 Earnings Snapshot - The Washington Post
Capricor Therapeutics (CAPR) Highlights Deramiocel Progress in Q - GuruFocus
Earnings call transcript: Capricor Therapeutics Q1 2025 reports wider loss, stock rises - Investing.com Australia
Capricor (CAPR) On Track for Duchenne Cardiomyopathy Therapy App - GuruFocus
Capricor Therapeutics reports Q1 EPS (53c), consensus (32c) - TipRanks
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
Capricor Therapeutics (CAPR) Sees Elevated Option Activity Ahead of Earnings | CAPR Stock News - GuruFocus
CAPR STOCK ALERT: Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Capricor Therapeutics (CAPR) Anticipates Q1 Earnings Report - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor - Bluefield Daily Telegraph
Capricor Therapeutics (CAPR) Appoints New Chief Medical Officer - GuruFocus
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer - The Manila Times
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. Investors of the Ongoing Investigation Into Potential Violations of Securities LawsCAPR - ACCESS Newswire
What To Expect From Capricor Therapeutics Inc (CAPR) Q1 2025 Ear - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
A Look Ahead: Capricor Therapeutics's Earnings Forecast - Nasdaq
ATTENTION CAPR SHAREHOLDERS: Investors Who Lost Money on Capricor Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation - ACCESS Newswire
Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday - Defense World
CAPR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Capricor Therapeutics, Inc. - ACCESS Newswire
New FDA Leadership Could Raise The Bar For Drug Approvals - Benzinga
Shareholders that lost money on Capricor Therapeutics, Inc. (CAPR) should contact Levi & Korsinsky about Securities Fraud InvestigationCAPR - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - GlobeNewswire Inc.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet - simplywall.st
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire
MetLife Investment Management LLC Makes New Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How the (CAPR) price action is used to our Advantage - news.stocktradersdaily.com
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Capricor falls 12% as FDA orders panel to discuss Duchenne cardiomyopathy asset - MSN
Capricor Therapeutics to Present First Quarter 2025 Financial Re - GuruFocus
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 | CAPR Stock News - GuruFocus
Capricor Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on May 13 - Nasdaq
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewswire
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duch - GuruFocus
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duchenne Treatment | CAPR Stock News - GuruFocus
FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy - Endpoints News
US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
Sector Update: Health Care Stocks Lower Monday Afternoon - marketscreener.com
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting, Shares Drop - GuruFocus
Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment - marketscreener.com
Capricor Share Slide 12% as FDA Calls Advisory Panel for Duchenne Cardiomyopathy Therapy - paginasiete.bo
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic - Asianet Newsable
Capricor falls after FDA to hold advisory meeting for cell therapy - TradingView
Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip | CAPR Stock News - GuruFocus
CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Completion of Mid-Cycle - GlobeNewswire
FDA Fast-Tracks Revolutionary DMD Heart Treatment as Capricor Clears Major Regulatory Hurdle - Stock Titan
Barclays PLC Has $1.24 Million Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co. - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus Target Price from Analysts - Defense World
Wells Fargo & Company MN Sells 4,641 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ: CAPR) Stock Gained 34.46% Over A Month – Any Room To Run? - Marketing Sentinel
Capricor Therapeutics Inc (CAPR) shows promising results - uspostnews.com
Capricor Therapeutics Inc (CAPR) receives an Overweight rating from Piper Sandler - knoxdaily.com
Legal & General Group Plc Grows Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Capricor Therapeutics Inc’s Market Journey: Closing Weak at 12.83, Down -1.53 - DWinneX
Russell Investments Group Ltd. Grows Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):